Athithi Verma
Eli Lilly has signed back-to-back collaborations with SanegeneBio and MeiraGTx, advancing its genetic medicine portfolio across RNA interference and ophthalmic gene therapy. Together, the agreements deepen Lilly’s position in next-generation RNA- and DNA-based therapeutics.
CMS’ Medicaid drug payment model links value-based pricing and international benchmarks to lower costs and improve patient outcomes. (Editorial illustration.) US government aims to lower Medicaid drug prices and align costs with global rates under new GENEROUS model The US government has launched a sweeping initiative to reduce prescription drug costs under the Medicaid program, … Read more
Thailand is letting patients fill hospital prescriptions at registered pharmacies under a new initiative expected to save households 32 billion baht annually. Officials say the program will ease private-sector pricing pressure and improve drug access nationwide.
Scilex Holding Company has announced an exclusive global license from Datavault AI to tokenize and monetize genomic, diagnostic, and therapeutic data ushering in a new digital framework for valuing real-world biotech assets. The agreement allows Scilex to use Datavault’s proprietary AI-driven platform to create a Biotech Exchange, a marketplace designed to securely trade and fund … Read more
In a major policy moment, Lilly and Novo Nordisk are in active talks with U.S. officials to cap obesity drug prices, aligning political pressure with market strategy.
CMS’s payment modernization plan seeks to trim inefficiencies, curb wasteful spending in wound care, and realign value in Medicare reimbursement. Providers brace for tighter margins as policymakers hail a new era of cost discipline.
Lepu Medical expands its biotech footprint through a licensing deal with Sidera Bio for MWN105, a triple-agonist drug targeting obesity and metabolic disorders, combining equity, milestone, and royalty gains in a global partnership.
Malaysia’s acceptance of U.S. FDA certificates under the new U.S.–Malaysia reciprocal trade deal.
Funeral reimbursement could transform U.S. organ donation access and equity.
Evernorth’s pricing model overhaul transforms drug access and reimbursement dynamics.